Erratum to: Progressive changes of orexin system in a rat model of 6-hydroxydopamine-induced Parkinson’s disease (Neurosci. Bull., (2010), 26, 5, (381–387), 10.1007/s12264-010-0410-9);Progressive changes of orexin system in a rat model of 6-hydroxydopamine- induced Parkinson's disease

Neuroscience Bulletin

Volumn 26, Issue 5, 2010, Pages 381-387

  Cui, Long Biao ^a   Li, Bo Wei ^a   Jin, Xiao Hang ^a   Zhao, Lin ^b   Shi, Juan ^a  

^a FOURTH MILITARY MEDICAL UNIVERSITY   (China)

^b YAN'AN UNIVERSITY   (China)

Author keywords

Degeneration; Orexin; Parkinson's disease; Sleep disturbance

Indexed keywords

OREXIN; OREXIN A; OXIDOPAMINE; TYROSINE 3 MONOOXYGENASE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL LOSS; CEREBROSPINAL FLUID EXAMINATION; CONTROLLED STUDY; DISEASE COURSE; ENZYME LINKED IMMUNOSORBENT ASSAY; HYPOTHALAMUS; IMMUNOHISTOCHEMISTRY; MALE; MEDIAL FOREBRAIN BUNDLE; MESENCEPHALON; NONHUMAN; PARKINSON DISEASE; PERIKARYON; RAT; SLEEP DISORDER; SLEEP WAKING CYCLE;

EID: 78650205346     PISSN: 16737067     EISSN: 19958218     Source Type: Journal    
DOI: 10.1007/s12264-016-0043-8     Document Type: Erratum

References (16)

1. Fronczek R, Baumann CR, Lammers GJ, Bassetti CL, Overeem S. Hypocretin/orexin disturbances in neurological disorders. Sleep Med Rev 2009, 13:9-22.
2. Lin L, Faraco J, Li R, Kadotani H, Rogers W, Lin X, et al. The sleep disorder canine narcolepsy is caused by a mutation in the hypocretin (orexin) receptor 2 gene. Cell 1999, 98:365-376.
3. Chemelli RM, Willie JT, Sinton CM, Elmquist JK, Scammell T, Lee C, et al. Narcolepsy in orexin knockout mice: molecular genetics of sleep regulation. Cell 1999, 98:437-451.
4. Nishino S, Ripley B, Overeem S, Lammers GJ, Mignot E. Hypocretin (orexin) deficiency in human narcolepsy. Lancet 2000, 355:39-40.
5. Hobson DE, Lang AE, Martin WR, Razmy A, Rivest J, Fleming J. Excessive daytime sleepiness and sudden-onset sleep in Parkinson disease: a survey by the Canadian Movement Disorders Group. JAMA 2002, 287:455-463.
6. Arnulf I, Bonnet AM, Damier P, Bejjani BP, Seilhean D, Derenne JP, et al. Hallucinations, REM sleep, and Parkinson's disease: a medical hypothesis. Neurology 2000, 55:281-288.
7. Drouot X, Moutereau S, Nguyen JP, Lefaucheur JP, Créange A, Remy P, et al. Low levels of ventricular CSF orexin/hypocretin in advanced PD. Neurology 2003, 61:540-543.
8. Fronczek R, Overeem S, Lee SY, Hegeman IM, van Pelt J, van Duinen SG, et al. Hypocretin (orexin) loss in Parkinson's disease. Brain 2007, 130:1577-1585.
9. Thannickal TC, Lai YY, Siegel JM. Hypocretin (orexin) cell loss in Parkinson's disease. Brain 2007, 130:1586-1595.
10. Asai H, Hirano M, Furiya Y, Udaka F, Morikawa M, Kanbayashi T, et al. Cerebrospinal fluid-orexin levels and sleep attacks in four patients with Parkinson's disease. Clin Neurol Neurosurg 2009, 111:341-344.
11. Poceta JS, Parsons L, Engelland S, Kripke DF. Circadian rhythm of CSF monoamines and hypocretin-1 in restless legs syndrome and Parkinson's disease. Sleep Med 2009, 10:129-133.
12. Mandel RJ, Spratt SK, Snyder RO, Leff SE. Midbrain injection of recombinant adeno-associated virus encoding rat glial cell linederived neurotrophic factor protects nigral neurons in a progressive 6-hydroxydopamine-induced degeneration model of Parkinson's disease in rats. Proc Natl Acad Sci U S A 1997, 94:14083-14088.
13. Chen CT, Dun SL, Kwok EH, Dun NJ, Chang JK. Orexin A-like immunoreactivity in the rat brain. Neurosci Lett 1999, 260:161-164.
14. Marinova-Mutafchieva L, Sadeghian M, Broom L, Davis JB, Medhurst AD, Dexter DT. Relationship between microglial activation and dopaminergic neuronal loss in the substantia nigra: a time course study in a 6-hydroxydopamine model of Parkinson's disease. J Neurochem 2009, 110:966-975.
15. Gerashchenko D, Murillo-Rodriguez E, Lin L, Xu M, Hallett L, Nishino S, et al. Relationship between CSF hypocretin levels and hypocretin neuronal loss. Exp Neurol 2003, 184:1010-1016.
16. Jeon BS, Jackson-Lewis V, Burke RE. 6-Hydroxydopamine lesion of the rat substantia nigra: time course and morphology of cell death. Neurodegeneration 1995, 4:131-137.